Literature DB >> 12774213

Deep brain stimulation for Parkinson's disease: the experience of the Policlinico-San Paolo Group in Milan.

F Tamma1, P Rampini, M Egidi, E Caputo, M Locatelli, A Pesenti, V Chiesa, G Ardolino, G Foffani, B Meda, M Pellegrini, A Priori.   

Abstract

Thirty patients with idiopathic Parkinson's disease were treated with deep brain stimulation electrode in the subthalamic nucleus. After surgery, the patients' best mean Unified Parkinson's Disease Rating Scale (UPDRS III) scores (medictionOFF-stimulatorON versus preoperative medicationOFF) were 77+/-14% at 3 months ( n=20 patients) and 72+/-14% at 12 months follow-up ( n=16). The mean reduction in therapy (expressed in levodopa dose equivalents in mg) was 68+/-25% at 12 months. Postoperative complications were rare, mostly mild, and reversible. Therapeutic success depends on a multidisciplinary team approach, meticulous patient selection, including patients' cognitive, psychic, and behavioral status, and patient and family lifestyles.

Entities:  

Mesh:

Year:  2003        PMID: 12774213     DOI: 10.1007/s100720300038

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  2 in total

1.  Operative techniques and morbidity with subthalamic nucleus deep brain stimulation in 100 consecutive patients with advanced Parkinson's disease.

Authors:  R R Goodman; B Kim; S McClelland; P B Senatus; L M Winfield; S L Pullman; Q Yu; B Ford; G M McKhann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

Review 2.  Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.

Authors:  Jens Volkmann; Alberto Albanese; Angelo Antonini; K Ray Chaudhuri; Carl E Clarke; Rob M A de Bie; Günther Deuschl; Karla Eggert; Jean-Luc Houeto; Jaime Kulisevsky; Dag Nyholm; Per Odin; Karen Østergaard; Werner Poewe; Pierre Pollak; Jose Martin Rabey; Olivier Rascol; Evzen Ruzicka; Michael Samuel; Hans Speelman; Olof Sydow; Francesc Valldeoriola; Chris van der Linden; Wolfgang Oertel
Journal:  J Neurol       Date:  2013-01-05       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.